RegenCen review

RegenCen's peptide page is unusually honest, and it is honest by subtraction. It names exactly what it prescribes — GLP-1 medications, sermorelin and platelet-rich plasma — and then names what it will not touch, citing the FDA's 2023 restriction of 17 compounds, listing BPC-157, ipamorelin and GHK-Cu as examples, and saying it will not offer them unless the FDA formally allows compounding pharmacies to make them again. In a category built on menu length, a practice that publishes a short list and explains the omissions is worth more than one advertising fifty molecules. The trade-offs are real: no price appears anywhere on the site (consultations are stated to be complimentary), and virtual visits reach only Michigan and Florida, so for most readers this is an in-person option.

RegenCen is a physician-led midlife, hormone and regenerative medicine practice with 23 locations — eleven across Michigan and twelve across Florida. Its services run bioidentical hormone therapy for women and men, testosterone therapy, medically guided weight loss with semaglutide and tirzepatide, sermorelin, NAD⁺ as IV drips and IM injections, platelet-rich plasma and platelet-rich fibrin, IV vitamin therapy, musculoskeletal pain treatment, hair restoration and women's sexual health. It is led by founder and chief medical officer Dr. Gustav Lo, MD, and publishes a team page of its nurse practitioners and physician assistants by region.

In-person first, with virtual appointments by video or phone for patients located in Michigan and Florida. The clinical philosophy is stated explicitly and is unusual: hormone replacement is treated as the foundation layer, peptides as a refinement applied only after that foundation is in place, and sermorelin specifically is described as most useful for patients already on hormone therapy who have hit a wall on a named complaint — with IGF-1 lab work used to judge whether someone is likely to benefit. Care runs under licensed medical providers with clinical review and guidance from Dr. Gustav Lo, and treatment is self-administered by injection between visits. The disclosure that distinguishes it is the negative one: the practice states it works only with therapies that have been studied extensively and whose clinical use is legally sound, and its peptide page discusses the FDA's 2023 restriction on 17 peptide compounds — naming BPC-157, ipamorelin and GHK-Cu — as compounds it does not supply, adding that it will not offer them until the FDA formally authorizes compounding pharmacies to resume. Two limits to weigh. There is no published price for anything, so cost is entirely a consultation conversation, though the consultation itself is stated to be free. And this is a regional practice with a wide footprint rather than a national telehealth service.

Nothing is published. No price appears for sermorelin, for NAD⁺, for hormone therapy or for GLP-1 medications anywhere on the public site. For a practice whose model is consultation-led and lab-guided, that is a defensible position — the dose and the protocol genuinely differ per patient, and a headline number would misrepresent it — but it does mean you cannot compare RegenCen against a telehealth platform before booking. Consultations are stated to be complimentary, so asking costs nothing. Ask three things at the consultation: what a month of sermorelin costs including the IGF-1 lab work that decides whether you start it, what an NAD⁺ IV session costs versus an IM injection and how many are proposed, and whether the comprehensive lab panel the program describes is billed separately. Ask too about medication sourcing, since the site does not state whether its sermorelin is compounded or by whom.

Prescription and physician-supervised, with a licensed provider deciding what is appropriate after lab work. Where medication is compounded it is not FDA-approved, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are; RegenCen does not state its sourcing publicly. On evidence, the short list is a feature. Sermorelin is a GHRH analog that stimulates your own pituitary to release growth hormone rather than supplying it, preserving the feedback loop exogenous growth hormone overrides — a real, well-characterized mechanism whose human outcome data thins badly beyond short-term IGF-1 movement, which is precisely why using IGF-1 to select patients is more defensible than selling it to everyone. NAD⁺ delivered by IV or IM has no controlled human outcome trials; the forms with human trial data are the oral precursors NR and NMN, which raise a blood NAD⁺ level rather than demonstrate a clinical benefit. Platelet-rich plasma is autologous — your own concentrated platelets — so it carries no immune-reaction risk, and its outcome evidence varies sharply by indication rather than being uniformly strong. The GLP-1 medications on the same page have the largest randomized evidence base of anything RegenCen offers. Individual results vary.